Genome and Company

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
GEN-001 is an oral microbiome therapeutic candidate developed to have immune modulating activities, resulting in potential partnership with immune checkpoint inhibitors(ICIs). GEN-001 consists a single-strain bacteria isolated from gut of healthy human volunteers that has been shown to activate dendritic cells, macrophages and T-cell response. In preclinical studies, GEN-001 has shown optimal safety margin and synergistic effects in combination with ICIs by enhancing the effect of suppressing the growth of both ICIs sensitive and resistant tumor models. Recently, the U.S FDA has accepted the IND application for GEN-001 for combination treatment with avelumab (BAVENCIO®) in patients with solid cancers. With this clearance, G&C will be the first Asian company to initiate a first-in-human trial of anti-cancer microbiome and anti-PD1-(L)1 combination treatment as a sole sponsor. The phase 1/1b clinical trial will be initiated at the US clinical sites within this year.
Ticker:
314130
Exchange:
KONEX (Korea New Exchange)
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
GEN-001
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CTO, Co-Founder
Genome and Company